Corrigendum to “Phase II evaluation of copanlisib, a selective inhibitor of Pi3kca, in patients with persistent or recurrent endometrial carcinoma harboring PIK3CA hotspot mutations: An NRG oncology study (NRG-GY008)” [Gynecol. Oncol. Rep. 31 (2020) 100532]

Detalles Bibliográficos
Autores principales: Santin, Alessandro D., Filiaci, Virginia, Bellone, Stefania, O'Cearbhaill, Roisin, Ratner, Elena S., Mathews, Cara A., Cantuaria, Guilherme, Gunderson, Camille C., Rutledge, Teresa, Buttin, Barbara M., Lankes, Heather A., Birrer, Michael J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Corrigendum
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7452617/
https://www.ncbi.nlm.nih.gov/pubmed/32885014
http://dx.doi.org/10.1016/j.gore.2020.100590

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7452617/
https://www.ncbi.nlm.nih.gov/pubmed/32885014
http://dx.doi.org/10.1016/j.gore.2020.100590

Ejemplares similares